A Multicenter, Long-Term, Rollover Extension Study of Rovalpituzumab Tesirine
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2019
At a glance
- Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AbbVie
- 20 Dec 2018 Planned End Date changed from 30 Aug 2023 to 5 Feb 2024.
- 20 Dec 2018 Planned primary completion date changed from 30 Aug 2023 to 5 Feb 2024.
- 21 Sep 2018 Status changed from not yet recruiting to recruiting.